Results 81 to 90 of about 2,985,698 (230)

Serum Neurofilament Light Chain: A Marker of Nervous System Damage in Myopathies

open access: yesFrontiers in Neuroscience, 2021
Purpose: Neurofilament light chain in serum (sNfL) has been suggested as a biomarker for the assessment of neuroaxonal damage. Since NfL are not expressed in muscle, elevated sNfL in patients with primary myopathies suggest additional nervous system ...
Annika Saak   +7 more
doaj   +1 more source

Diagnosed After Birth—But Detectable Before? A Cohort Study of Prenatal Testing Potential

open access: yesPrenatal Diagnosis, EarlyView.
ABSTRACT Objective To evaluate the yield of prenatal genetic testing in infants with a confirmed genetic diagnosis. Methods We retrospectively reviewed records of infants with a genetic diagnosis who were evaluated using a standardized genetic consult and testing approach. The predicted yield of various prenatal genetic sceening and diagnostic tools in
Allison Schartman   +6 more
wiley   +1 more source

Pediatric feeding and swallowing rehabilitation: An overview [PDF]

open access: yes, 2017
Children with neurological disabilities frequently have problems with feeding and swallowing. Such problems have a significant impact on the health and well-being of these children and their families.
Arvedson   +62 more
core   +11 more sources

Calcitriol increases MBNL1 expression and alleviates myotonic dystrophy phenotypes in HSALR mouse models

open access: yesJournal of Translational Medicine, 2022
Background Myotonic dystrophy type 1 (DM1), one of the most common forms of adult-onset muscular dystrophy, is caused by abnormally expanded CTG repeats in the 3′ untranslated region of the DMPK gene.
Kun Huang   +8 more
doaj   +1 more source

Super‐Response to Guselkumab Treatment in Patients With Moderate‐to‐Severe Psoriasis: Real‐World Data With Up to Five Years of Follow‐Up in The Czech Republic

open access: yesInternational Journal of Dermatology, EarlyView.
Super‐response to Guselkumab. ABSTRACT Background Guselkumab, a selective interleukin (IL)‐23 inhibitor, is approved for the treatment of moderate‐to‐severe plaque psoriasis. While randomized clinical trials have introduced the concept of “super‐responders” (SRe)—patients achieving complete skin clearance (Psoriasis Area and Severity Index [PASI] 100 ...
Martina Kojanova   +76 more
wiley   +1 more source

Geographical distribution of eight neuromuscular disorders in the Netherlands based on a nationwide registry

open access: yesRare
Neuromuscular disorders are a very heterogeneous group of diseases and comprise a large number of patients. Epidemiological key figures on incidence, prevalence and mortality serve as basic information for individualised and public health care and ...
Johanna C.W. Deenen   +8 more
doaj   +1 more source

Sleep and breathing disorders in myotonic dystrophy type 2

open access: yesActa Neurologica Scandinavica, 2015
In patients who exhibit myotonic dystrophy type 1 (DM1), sleep disorders and breathing impairments are common; however, in those with DM type 2 (DM2), limited studies on polysomnography (PSG) and none on phrenic compound motor action potential (CMAP ...
L. Leonardis, R. Blagus, L. D. Grošelj
semanticscholar   +1 more source

Comparative (computational) analysis of the DNA methylation status of trinucleotide repeat expansion diseases [PDF]

open access: yes, 2013
Copyright © 2013 Mohammadmersad Ghorbani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is ...
Ghorbani, M   +3 more
core   +4 more sources

Narcolepsy and rapid eye movement sleep

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Since the first description of narcolepsy at the end of the 19th Century, great progress has been made. The disease is nowadays distinguished as narcolepsy type 1 and type 2. In the 1960s, the discovery of rapid eye movement sleep at sleep onset led to improved understanding of core sleep‐related disease symptoms of the disease (excessive ...
Francesco Biscarini   +4 more
wiley   +1 more source

REM behavior disorder in myotonic dystrophy type 2 [PDF]

open access: yesNeurology, 2012
A 63-year-old woman with myotonic dystrophy type 2[1][1] and obstructive sleep apnea by polysomnography, not on medications traditionally known to cause REM behavior disorder (RBD), had dream-enacting behavior (DEB).
Sudhansu, Chokroverty   +3 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy